CVRx reports Q4 EPS (43c), consensus (38c)

Reports Q4 revenue $15.34M, consensus $15.22M…Active implanting centers for 2024 increased to 223, a 25% increase since December 31, 2023 “We capped off a very strong 2024 with a solid fourth quarter, which included 41% growth in U.S. heart failure revenue as well the successful achievement of multiple critical reimbursement milestones,” said Kevin Hykes, President and CEO of CVRx (CVRX). “As we look to 2025, we are focused on three key strategic priorities to drive Barostim toward becoming the standard of care – building a world-class sales organization, supporting the development of sustainable Barostim programs to drive deeper utilization, and addressing barriers to adoption. With the organization-wide success we saw in 2024, in combination with our key priorities for 2025, we are well-positioned to drive the continued adoption of Barostim therapy.”